Compare Prospect Capital Corporation (PSEC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prospect Capital Corporation vs BIO-TECHNE Corp — how do they compare? Prospect Capital Corporation trades at $2.14 (market cap $1.08B), while BIO-TECHNE Corp trades at $71.73 (market cap $11.16B). The key difference: BIO-TECHNE Corp is far larger — about 10.3× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (23.26%). Which is the better fit depends on your goals.
| PSEC | TECH | |
|---|---|---|
Market Cap | $1.08B | $11.16B |
Sector | Financials | Health |
52-Week High | $3.47 | $72.12 |
52-Week Low | $2.15 | $43.31 |
Dividend Yield | 23.26% | 0.45% |
Enterprise Value | — | $11.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prospect Capital Corporation (PSEC) trades at $2.15, down 4.44% on the day, reflecting persistent bearish technical signals. The company's fundamentals are challenged, with negative revenue of -$407M and a net income margin of -495.94% for 2025, though it has beaten EPS estimates for the last three consecutive quarters. Recent corporate actions include regular dividend payments, while news highlights portfolio activity and deep discounts to net asset value.
The outlook remains cautious due to weak profitability and a bearish analyst consensus. The primary opportunity lies in the stock's high yield and significant discount to book value, but risks include ongoing revenue volatility, declining net asset value, and skepticism about portfolio quality. Investors should weigh income potential against fundamental deterioration.
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
